Prescribing hemodialysis: The role of gender

Advances in Renal Replacement Therapy

Volumn 10, Issue 1, 2003, Pages 71-77

  Depner, Thomas A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dialysis dose; Dialysis prescription; Gender; HEMO Study; Hemodialysis; Uremic toxicity

Indexed keywords

UREMIC TOXIN;

BODY SIZE; DISEASE PREDISPOSITION; GENDER; HEMODIALYSIS; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MORTALITY; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; UNITED STATES;

EID: 0037289309     PISSN: 10734449     EISSN: None     Source Type: Journal    
DOI: 10.1053/jarr.2003.50007     Document Type: Review

References (30)

1. Lowrie EG, Laird NM, Parker TF, et al: Effect of the hemodialysis prescription on patient morbidity: Report from the National Cooperative Dialysis Study. N Engl J Med 305:1176-1181, 1981
2. Gotch FA, Sargent JA: A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int 28:526-534, 1985
3. Laird NM, Berkey CS, Lowrie EG: Modeling success or failure of dialysis therapy: the National Cooperative Dialysis Study. Kidney Int 23:101-106, 1983 (suppl)
4. Depner TA, Daugirdas JT: Does gender influence the effect of dialysis dose on mortality? Results of the HEMO Study. J Am Soc Nephrol 13:422A, 2002 (abstr)
5. Wolfe RA, Held PJ, Hulbert-Shearon TE, et al: URR >75% is associated with lower mortality among females but not among males. J Am Soc Nephrol 13:20A, 2002 (abstr)
6. West GB, Brown JH, Enquist BJ: A general model for the origin of allometric scaling laws in biology [see comments]. Science 276:122-126, 1997
7. Schmidt-Nielsen K: Scaling: why is animal size so important? in Calder WA (ed): Size, Function, and Life History. Cambridge, MA, Harvard Univ Press, 1984
8. Wolfe RA, Ashby VB, Daugirdas JT, et al: Body size, dose of hemodialysis, and mortality. Am J Kidney Dis 35:80-88, 2000
9. Port FK, Ashby VB, Dhingra RK, et al: Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. J Am Soc Nephrol 13:1061-1066, 2002
10. Coppack SW: Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 60:349-356, 2001
11. Depner TA: Single-compartment model, in Prescribing Hemodialysis: a guide to urea modeling, chap 4. Boston, MA, Khewar Acad Publishers, 1991, pp 65-89
12. Lowrie EG: History and organization of the National Cooperative Dialysis Study. Kidney Int Suppl 13:S1-S7, 1983
13. Vanholder R, Schoots A, Cramers C, et al: Hippuric acid as a marker, in Ringoir S, Vanholder R, Massry S (eds): Uremic Toxins. New York, NY, Plenum Publishing Co, 1987, pp 59-67
14. Depner TA: Hemodialysis urea modeling: the basics. Semin Dial 4:179-184, 1991
15. Frankenfield DL, McClellan WM, Helgerson SD, et al: Relationship between urea reduction ratio, demographic characteristics, and body weight for patients in the 1996 National ESRD Core Indicators Project. Am J Kidney Dis 33:584-591, 1999
16. Leavey SF, McCullough K, Hecking E, et al: Body mass index and mortality in 'healthier' as compared with 'sicker' haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 16:2386-2394, 2001
17. Painter P: The importance of exercise training in rehabilitation of patients with end-stage renal disease. Am J Kidney Dis 24:S2-9; discussion S31-2, 1994
18. Teraoka S, Toma H, Nihei H, et al: Current status of renal replacement therapy in Japan. Am J Kidney Dis 25:151-164, 1995
19. McClellan WM, Soucie JM, Flanders WD: Mortality in end-stage renal disease is associated with facility-to-facility differences in adequacy of hemodialysis. J Am Soc Nephrol 9:1940-1947, 1998
20. Owen WF, Jr., Lew NL, Liu Y, et al: The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 329:1001-1006, 1993
21. Held PJ, Port FK, Wolfe RA, et al: The dose of hemodialysis and patient mortality. Kidney Int 50:550-556, 1996
22. Chertow GM, Owen WF, Lazarus JM, et al: Exploring the reverse J-shaped curve between urea reduction ratio and mortality. Kidney Int 56:1872-1878, 1999
23. Owen WF, Jr., Coladonato J, Szczech L, et al: Explaining counter-intuitive clinical outcomes predicted by Kt/V. Semin Dial 14:268-270, 2001
24. Owen WF, Jr., Chertow GM, Lazarus JM, et al: Dose of hemodialysis and survival: Differences by race and sex. J Am Med Assoc 280:1764-1768, 1998
25. U.S.Renal Data System: USRDS annual report, 2001. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2001
26. Ifudu O, Mayers JD, Cohen LS, et al: Correlates of vascular access and nonvascular access-related hospitalizations in hemodialysis patients. Am J Nephrol 16:118-123, 1996
27. Ifudu O, Feldman J, Friedman EA: The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med 334:420-425, 1996
28. Movilli E, Cancarini GC, Zani R, et al: Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients. Nephrol Dial Transplant 16:111-114, 2001
29. Richardson D: Clinical factors influencing sensitivity and response to epoetin. Nephrol Dial Transplant 17:53-59, 2002 (suppl)
30. Eknoyan G, Beck GJ, Cheung AK, et al: Effect of dialysis dose and membrane flux on mortality and morbidity in chronic hemodialysis patients: primary results of the HEMO study. N Engl J Med 347:2010-2019, 2000